144 related articles for article (PubMed ID: 35247898)
41. The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning.
Chen Y; Sun Z; Chen W; Liu C; Chai R; Ding J; Liu W; Feng X; Zhou J; Shen X; Huang S; Xu Z
Front Immunol; 2021; 12():685992. PubMed ID: 34262565
[TBL] [Abstract][Full Text] [Related]
42. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
43. Identification of prognostic and immune-related gene signatures in the tumor microenvironment of endometrial cancer.
Wang G; Wang D; Sun M; Liu X; Yang Q
Int Immunopharmacol; 2020 Nov; 88():106931. PubMed ID: 32889237
[TBL] [Abstract][Full Text] [Related]
44. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
Ioannides CG; Whiteside TL
Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
[TBL] [Abstract][Full Text] [Related]
45. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
46. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Spranger S; Sivan A; Corrales L; Gajewski TF
Adv Immunol; 2016; 130():75-93. PubMed ID: 26923000
[TBL] [Abstract][Full Text] [Related]
47. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Hurwitz AA; Watkins SK
Cancer Immunol Immunother; 2012 Feb; 61(2):289-293. PubMed ID: 22237887
[TBL] [Abstract][Full Text] [Related]
48. Vascular Microenvironment, Tumor Immunity and Immunotherapy.
Lamplugh Z; Fan Y
Front Immunol; 2021; 12():811485. PubMed ID: 34987525
[TBL] [Abstract][Full Text] [Related]
49. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Li J; Yuan S; Norgard RJ; Yan F; Sun YH; Kim IK; Merrell AJ; Sela Y; Jiang Y; Bhanu NV; Garcia BA; Vonderheide RH; Blanco A; Stanger BZ
Cancer Discov; 2021 Mar; 11(3):736-753. PubMed ID: 33158848
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of immune evasion in breast cancer.
Bates JP; Derakhshandeh R; Jones L; Webb TJ
BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
[TBL] [Abstract][Full Text] [Related]
52. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
53. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
54. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime.
Pradip D; Jennifer A; Nandini D
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502029
[TBL] [Abstract][Full Text] [Related]
55. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
56. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
Tsai HF; Hsu PN
J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
[TBL] [Abstract][Full Text] [Related]
57. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy.
Wang JZ; Zhang YH; Guo XH; Zhang HY; Zhang Y
Int Immunopharmacol; 2016 Jul; 36():73-85. PubMed ID: 27111515
[TBL] [Abstract][Full Text] [Related]
58. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
Li S; Bennett ZT; Sumer BD; Gao J
Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
[TBL] [Abstract][Full Text] [Related]
59. Metabolic Barriers to T Cell Function in Tumors.
Sugiura A; Rathmell JC
J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
[TBL] [Abstract][Full Text] [Related]
60. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]